KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Goodwill (2020 - 2025)

Recursion Pharmaceuticals' Goodwill history spans 6 years, with the latest figure at $162.2 million for Q4 2025.

  • For Q4 2025, Goodwill rose 8.92% year-over-year to $162.2 million; the TTM value through Dec 2025 reached $162.2 million, up 8.92%, while the annual FY2025 figure was $162.2 million, 8.92% up from the prior year.
  • Goodwill reached $162.2 million in Q4 2025 per RXRX's latest filing, roughly flat from $162.0 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $164.3 million in Q2 2025 to a low of $801000.0 in Q1 2021.
  • Average Goodwill over 5 years is $56.2 million, with a median of $52.1 million recorded in 2023.
  • Peak YoY movement for Goodwill: soared 7455.06% in 2023, then dropped 13.98% in 2024.
  • A 5-year view of Goodwill shows it stood at $801000.0 in 2021, then changed by 0.0% to $801000.0 in 2022, then skyrocketed by 6398.88% to $52.1 million in 2023, then surged by 185.99% to $148.9 million in 2024, then increased by 8.92% to $162.2 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Goodwill are $162.2 million (Q4 2025), $162.0 million (Q3 2025), and $164.3 million (Q2 2025).